Your treatment at a glance
Tirzepatide Program
Dual GIP/GLP-1 receptor agonist.
- Status
- Unavailable
- Clinical review
- Required before treatment
- Next step
- Check back soon
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Prescription required.
Product images are for illustration only. Packaging may vary.
Availability
Tirzepatide Program
Compounded tirzepatide with clinician oversight for accelerated metabolic outcomes. Submit your questionnaire to get started.
$249.00
Program Highlights
- Initial clinician consult and protocol design
- Full titration ladder — 2.5 mg through 15 mg/week
- Compounded vials from a licensed US pharmacy
- Unlimited messaging with your clinical team
Medications and treatments are subject to a valid prescription issued by a licensed healthcare provider.
What's included
Every treatment on Pillar comes with the same clinician-led care — no matter which program you start.
Program terms are provided by the care partner and dispensing pharmacy.
Everything you need,
nothing you don't.

What is Tirzepatide Program?
Tirzepatide acts on both GIP and GLP-1 receptors, often producing faster weight loss than single-pathway GLP-1s. Our program includes the same clinical infrastructure, with titration tuned to tolerance — and every dose in the ladder covered by your treatment plan. Current details are provided by the care partner and dispensing pharmacy. Submit your questionnaire to begin.
Included in your program
- Initial clinician consult and protocol design
- Full titration ladder — 2.5 mg through 15 mg/week
- Compounded vials from a licensed US pharmacy
- Unlimited messaging with your clinical team
Who's eligible?
- BMI 27+ with comorbidities, or BMI 30+
- Adults 18+ in eligible US states
Important safety information
Common side effects, who Tirzepatide Program is not for, and what to tell your clinician. A summary of key warnings, not complete prescribing information.
Explore related programs
Common questions,
answered.
Open any question to read the complete answer.

